Malignant Hyperthermia Susceptibility Panel
Use
This test is designed for individuals who have clinical symptoms or a family history of malignant hyperthermia susceptibility. It is intended for individuals who exhibit symptoms such as severe muscle rigidity, tachycardia, hypercapnia, hyperthermia, or rhabdomyolysis when exposed to specific anesthetic agents. It may help confirm a diagnosis and inform medical management and treatment strategies for patients and their families.
Special Instructions
Not provided.
Limitations
The panel is specific to changes in three genes associated with malignant hyperthermia susceptibility. Negative results do not preclude the possibility of malignant hyperthermia susceptibility due to variants in genes not included in this panel. The test has not been FDA-cleared or approved, and its performance characteristics were validated by PreventionGenetics under CLIA guidelines.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided